MEDICAL POLICY – 7.03.04
Isolated Small Bowel Transplant

BCBSA Ref. Policy: 7.03.04, 7.03.14
Effective Date: Nov. 1, 2019
Last Revised: Oct. 4, 2019
Replaces: 7.03.511

RELATED MEDICAL POLICIES:
7.03.05 Small Bowel/Liver and Multivisceral Transplant

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING
RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

An organ transplant is the surgical process of replacing a severely diseased organ with a healthy one from a donor. The donated organ can come from a living person or a person who passed away from an accident or illness. Organ failure is the most common reason a transplant is needed. Organ failure can occur because of illness, injury, or birth defect. There are many factors that go into finding a donor organ that matches. These include blood type and the size of the organ. Other factors include how long a person has been on the waiting list, the level of illness, and the distance the donated organ must be transported. This policy describes when transplanting a small bowel may be considered medically necessary. This policy notes that a plan physician will review solid organ transplant requests together with the criteria of the transplant center.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria
<table>
<thead>
<tr>
<th>Transplant</th>
<th>Medical Necessity</th>
</tr>
</thead>
</table>
| **Small bowel transplant using cadaveric intestine** | A small bowel transplant using cadaveric intestine may be considered medically necessary in adult and pediatric patients with All of the following:  
  - Patients with intestinal failure  
    - characterized by loss of absorption and the inability to maintain protein-energy, fluid, electrolyte, or micro nutrient balance; and  
  - Patients who have established long-term dependence on total parenteral nutrition (TPN); and  
  - Patients who are developing or have developed severe complications due to total parenteral nutrition |

<table>
<thead>
<tr>
<th>Small bowel transplant using a living donor</th>
<th>A small bowel transplant using a living donor may be considered medically necessary only when a cadaveric intestine is not available for transplantation in a patient who meets the criteria noted above for a cadaveric intestinal transplant.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Small bowel retransplant</strong></td>
<td>A small bowel retransplant may be considered medically necessary after a failed primary small bowel transplant.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transplant</th>
<th>Investigational</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Small bowel transplant</strong></td>
<td>A small bowel transplant is considered investigational for adult and pediatric patients with intestinal failure who can tolerate total parenteral nutrition.</td>
</tr>
<tr>
<td><strong>HCV (hepatitis C)- viremic organs</strong></td>
<td>The transplantation of HCV-viremic solid organs (kidney, lung, heart, liver, small bowel, pancreas) to an HCV non-viremic recipient combined with direct-acting antiviral treatment for HCV is considered investigational.</td>
</tr>
</tbody>
</table>

**Documentation Requirements**

The patient’s medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:
- Office visit notes that contain the relevant history and physical supporting that patient has intestinal failure, has had long-term dependence on TPN, and has now developed severe
Documentation Requirements

complications due to the TPN. Specify if the request is for cadaveric, living donor, or retransplantation

Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>44135</td>
<td>Intestinal allotransplantation; from cadaver donor</td>
</tr>
<tr>
<td>44136</td>
<td>Intestinal allotransplantation; from living donor.</td>
</tr>
<tr>
<td>HCPCS</td>
<td></td>
</tr>
<tr>
<td>S2152</td>
<td>Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre and posttransplant care in the global definition</td>
</tr>
</tbody>
</table>

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Small Bowel-Specific Criteria

Intestinal failure results from surgical resection, congenital defect, or disease-associated loss of absorption and is characterized by the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance. Short bowel syndrome is one case of intestinal failure.

Patients who are developing or have developed severe complications due to total parenteral nutrition (TPN) include, but are not limited to, the following: multiple and prolonged hospitalizations to treat TPN-related complications (especially repeated episodes of catheter-related sepsis) or the development of progressive liver failure. In the setting of progressive liver failure, small bowel transplant may be considered a technique to avoid end-stage liver failure related to chronic TPN, thus avoiding the necessity of a multivisceral transplant. In those
receiving TPN, liver disease with jaundice (total bilirubin >3 mg/dL) is often associated with development of irreversible, progressive liver disease. The inability to maintain venous access is another reason to consider small bowel transplant in those who are dependent on TPN.

Contraindications

Potential contraindications for solid organ transplant are subject to the judgment of the transplant center include the following:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage diseases not attributed to intestinal failure
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.

Benefit Application

See member’s plan contract language for organ transplant benefits and specific benefits related to transport, lodging, and donor services. Please note limitations in coverage based on the transplant benefit, if applicable.

Evidence Review

Description

A small bowel transplant may be performed as an isolated procedure or in conjunction with other visceral organs, including the liver, duodenum, jejunum, ileum, pancreas, or colon. Isolated
small bowel transplant is commonly performed in patients with short bowel syndrome. Small bowel/liver transplants and multivisceral transplants are considered in a Related Policy.

Background

Small Bowel Syndrome

Short bowel syndrome is a condition in which the absorbing surface of the small intestine is inadequate due to extensive disease or surgical removal of a large portion of the small intestine. In adults, etiologies of short bowel syndrome include ischemia, trauma, volvulus, and tumors. In children, gastroschisis, volvulus, necrotizing enterocolitis, and congenital atresia are predominant causes.

Treatment

The small intestine, particularly the ileum, can adapt to some functions of the diseased or removed portion over a period of one to two years. Prognosis for recovery depends on the degree and location of small intestine damage. Therapy focuses on achieving adequate macro- and micronutrient uptake in the remaining small bowel. Pharmacologic agents have been studied to increase villous proliferation and slow transit times, and surgical techniques have been advocated to optimize remaining small bowel.

However, some patients with short bowel syndrome are unable to obtain adequate nutrition from enteral feeding and become chronically dependent on total parenteral nutrition. Patients with complications from total parenteral nutrition may be considered candidates for a small bowel transplant. Complications include catheter-related mechanical problems, infections, hepatobiliary disease, and metabolic bone disease. While cadaveric intestinal transplant is the most commonly performed transplant, there has been a recent interest in using living donors.

Intestinal transplants (including multivisceral and bowel/liver) represent a small minority of all solid organ transplants. In 2016, 147 intestinal transplants were performed in the U. S.; all were from cadaver donors.¹
Summary of Evidence

For individuals who have intestinal failure who receive a small bowel transplant, the evidence includes case series. The relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Small bowel transplant is infrequently performed, and only relatively small case series, generally single-center, are available. Risks after small bowel transplant are high, particularly related to infection, but may be balanced against the need to avoid the long-term complications of total parenteral nutrition dependence. In addition, early small bowel transplant may obviate the need for a later combined liver/small bowel transplant. Transplantation is contraindicated in patients in whom the procedure is expected to be futile due to comorbid disease or in whom posttransplantation care is expected to worsen comorbid conditions significantly. Guidelines and U.S. federal policy no longer view HIV infection as an absolute contraindication for solid organ transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have failed small bowel transplant without contraindication(s) for retransplant who receive a small bowel retransplant, the evidence includes case series. The relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Data from a small number of patients undergoing retransplantation are available. Although limited in quantity, the available data have suggested a reasonably high survival rate after small bowel retransplantation in patients who continue to meet criteria for transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are HCV non-viremic who have end-stage organ disease and are candidates for a solid organ transplant such as for small bowel or pancreas, evidence for the use of HCV viremic donor organs as an alternative to continuing appropriate medical treatment and remaining on the transplant wait-list has not been reported in the last five years in the published literature. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in June 2019 did not identify any ongoing or unpublished trials that would likely influence this review.
Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from two physician specialty societies and two academic medical centers while this policy was under review in 2009. The consensus of those providing input was that small bowel transplant should be performed in patients who are developing severe total parenteral nutrition-related complications and that small bowel transplant from living donors may be considered when cadaveric intestinal transplants are not available.

Practice Guidelines and Position Statements

American Gastroenterological Association

The American Gastroenterological Association (2003) produced a medical position statement on short bowel syndrome and intestinal transplantation.30 It recommended dietary, medical, and surgical solutions. Indications for intestinal transplantation mirrored those of the Centers for Medicare & Medicaid Services. The guidelines acknowledged the limitations of transplant for these patients. The statement recommended the following Medicare-approved indications, pending availability of additional data:

1. "Impending or overt liver failure...

2. Thrombosis of major central venous channels...

3. Frequent central line-related sepsis...

4. Frequent severe dehydration."

American Society of Transplantation

The American Society of Transplantation (2001) issued a position paper on indications for pediatric intestinal transplantation.31 The Society listed the following disorders in children as
potentially treatable by intestinal transplantation: short bowel syndrome, defective intestinal motility, and impaired enterocyte absorptive capacity. Contraindications for intestinal transplant to treat pediatric patients with intestinal failure are similar to those of other solid organ transplants: profound neurologic disabilities, life-threatening comorbidities, severe immunologic deficiencies, nonresectable malignancies, autoimmune diseases, and insufficient vascular patency.

The American Society of Transplantation (2017) convened a consensus conference of experts to address issues related to the transplantation of hepatitis C virus (HCV) viremic solid organs into HCV non-viremic recipients and concluded that the transplantation of organs from HCV viremic donors into HCV-negative recipients should be conducted only under monitored IRB-approved protocols and studies.

**Medicare National Coverage**

The Centers for Medicare & Medicaid have a national coverage determination on intestinal and multivisceral transplantation. The determination covers these types of transplants only when performed for patients who have failed total parenteral nutrition (TPN) and only when performed in centers that meet approval criteria.

1. **Failed TPN**

   The TPN delivers nutrients intravenously, avoiding the need for absorption through the small bowel. TPN failure includes the following:
   
   - Impending or overt liver failure due to TPN induced liver injury...
   - Thrombosis of the major central venous channels; jugular, subclavian, and femoral veins.
   - Frequent line infection and sepsis.
   - Frequent episodes of severe dehydration despite intravenous fluid supplement in addition to TPN.

2. **Approved Transplant Facilities**

   The criteria for approval of centers will be based on a volume of 10 intestinal transplants per year with a 1-year actuarial survival of 65 percent using the Kaplan-Meier technique.
Regulatory Status

Small bowel transplantation is a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration.

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation Title 21, parts 1270 and 1271. Small bowel transplants are included in these regulations.

References


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/19</td>
<td>New policy, approved October 4, 2019. This policy replaces policy 7.03.511 which is now deleted. Policy created with literature review through June 2019. A cadaveric or living donor small bowel transplant may be considered medically necessary when criteria are met. Policy statement on transplantation of HCV viremic organs is taken from BCBSA policy 7.03.14.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

Getting Help in Other Languages

This Notice has Important Information. This notice may have important dates in it. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

Arabic (Amharic):
لا تلمع راهنا لابي وتفت قحار ونُزلت عن واندبلو وأيادها بعد وكرمها في بيض أوروبا. هيذا الإشعار علاقات من نموذجها الذي ي proprietà على أي نسخة. هذه المناخ بسردية بيدرة مساعدة في هذا الإشعار. وقد تتطابق إجراء بيك توزيع جميع للتقرير على تطوير مادة الصحافة أو السعادة في دفع الكود نقي قحل تعديل النظام من أوروبا لتغطية يدي. أصل 800-722-1471 (TTY: 800-842-5357) م التهديد.

Chinese (Chinese):

عربي (Arabic):

عربية (Arabic):

獲取幫助在其他語言

這個注意事項有重要資訊。這個注意事項可能會有重要日期。你可能需要在截止日期之前採取行動，以保留你的健康保險或費用補貼。你有權利免費以您的母語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357).

Oromo (Afaric):


佛朗西斯克 (法语):


Getting Help in Other Languages

This Notice has Important Information. This notice may have important dates in it. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

Italiano (Italian):

Japanese (Japanese):
この通知には重要な情報が含まれています。この通知には、Premera Blue Crossの申請または補償範囲に関する重要な情報を含まれている場合があります。この通知には記載されている情報がある重要な日付をご確認ください。健康保険や貿易データを維持するには、特定の期日までに行動を取らないとならない場合があります。この告示の言語による情報とサポートが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話ください。

한국어 (Korean):
본 문서에서는 중요한 정보가 들어 있습니다. 즉 이 문서는 귀하의 신청에 관하여 그리고 Premera Blue Cross를 통한 커버리지에 관한 정보를 포함하고 있을 수 있습니다. 귀하의 신청 또는 커버리지에 대한 추가 정보를 원하시면, 제공된 정보를 참조하시기 바랍니다. 귀하의 신청 또는 커버리지에 대한 추가 정보를 원하시는 경우, 800-722-1471 (TTY: 800-842-5357)로 전화하십시오.

罗马尼亚 (Romanian):

Русский (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется привести к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

Español (Spanish):
Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

Tagalog (Tagalog):
Ang Paunawa na ito ay naglalaman ng mahalagang impormasyon. Ang paunawa na ito ay maaring nagkarugos ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagpakawang pamamanhag ng Premera Blue Cross. Maaaring maaagap ang iyong pag-unawa sa kahalagahan ng Premera Blue Cross. It is posible na mayroon kaong impormasyon na maaaring ikatalak ng iyong pag-unawa o panahon upang maapantay ang iyong pagpakawang sa kahalagahan ng tulong na walang gastos. May karanasan ka na makuha ng ganitong impormasyon at tulong sa iyong wika ng walang gastos. Tumawag sa 800-722-1471 (TTY: 800-842-5357).

ไทย (Thai):
ประกาศที่นี่มีข้อมูลสำคัญ ประกาศนี้ต้องการให้คุณทราบเกี่ยวกับการยื่นคำขอการช่วยเหลือสุขภาพของคุณ Premera Blue Cross และฉันขอแนะนำในกรณีที่คุณต้องการ สถานการณ์ในภูมิภาคที่มีความเสี่ยงสูงอาจทำให้การบริการช่วยเหลือสุขภาพของคุณไม่สามารถต้องการช่วยเหลือได้ สำหรับข้อมูลเพิ่มเติม กรุณาติดต่อ Premera Blue Cross.

Polskie (Polish):
To ogłoszenie może zawierać ważne informacje. To ogłoszenie może zawierać ważne informacje odnośnie Państwa wniosku lub zakresu świadczeń poprzez Premera Blue Cross. Prosimy zwrócić uwagę na kluczowe daty, które mogą być zawarte w tym ogłoszeniu aby nie przekroczyć terminów w przypadku utraty polisy ubezpieczeniowej lub pomocy związanej z kosztami. Macie prawo do bezpłatnej informacji we własnym języku. Zapoznajcie się z 800-722-1471 (TTY: 800-842-5357).

Português (Portuguese):
Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir datas importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde ou ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para 800-722-1471 (TTY: 800-842-5357).

Tiếng Việt (Vietnamese):

Український (Ukrainian):
Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страхувального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дозвоніться за номером телефону 800-722-1471 (TTY: 800-842-5357).

Français (French):

English (English):
This notice contains important information. This notice may contain important information about your application or coverage by Premera Blue Cross. It is possible that there are important dates in this notice. It may be necessary to follow the deadlines to maintain your coverage of health or assistance. You have the right to get this information and help in your language and without charge. Call 800-722-1471 (TTY: 800-842-5357).